Influenza Antibody Research Articles

Seroprevalence of Avian Influenza in Guinea Fowls in Some Districts in the Upper East Region of Ghana.

The guinea fowl (Numida meleagris) holds significant agricultural importance in Ghana, particularly in the Northern, Upper East and Upper West Regions. Despite their economic and cultural significance, guinea fowls face a potential threat from avian influenza, a global concern for its adverse impact on poultry populations. This study assessed the seroprevalence of the virus in mature guinea fowls in the Upper East Region. A cross-sectional survey was conducted in three districts within the Upper East Region from April to June 2023. Blood samples were collected from 397 guinea fowls that are over 4 weeks old, and seroprevalence was determined using ID Screen Influenza A Antibody Competition Enzyme-linked immunosorbent assay (ELISA). The study analysed demographic factors such as sex, age and source of birds, employing statistical methods to establish associations. Among the sampled guinea fowls, 24.7% tested positive for avian influenza antibodies, whereas 75.3% were seronegative. Age did not show statistically significant associations with seroprevalence, but intriguing patterns were observed. Adult guinea fowls exhibited higher seroprevalence (23.7%) compared to growers (1.0%). The source of birds showed no significant association, but birds from slaughter points demonstrated higher seroprevalence (11.6%) compared to households (5.0%) and live bird markets (8.1%). In conclusion, the study underscores the importance of monitoring avian influenza in guinea fowls to implement effective control measures. The presence of antibodies suggests guinea fowls may contribute to virus transmission in the Upper East Region. The study recommends ongoing nationwide surveillance to assess the true prevalence of avian influenza in guinea fowls across Ghana.

Highly pathogenic avian influenza (HPAI) H5 virus exposure in domestic cats and rural stray cats, the Netherlands, October 2020 to June 2023.

BackgroundHighly pathogenic avian influenza (HPAI) H5Nx and human H1N1pdm2009 influenza viruses can infect cats. Infections in cats may result in viral adaptations or recombinant viruses, which may facilitate zoonotic transfer.AimWe aimed to investigate the presence of HPAI H5 clade 2.3.4.4 and H1 influenza viruses and antibodies to these viruses in domestic and rural stray cats in the Netherlands and factors associated with exposure.MethodsSera from stray and domestic cats, sampled 2020-2023, were analysed by ELISA and confirmed by hemagglutination inhibition assay (HAI) and pharyngeal swabs and lung tissue for influenza A virus by RT-qPCR.ResultsIn 701 stray cats, 83 (11.8%; 95% confidence interval (CI): 9.5-14.5) sera were positive for HPAI H5 and 65 findings were confirmed. In HAI, two sera were positive for both HPAI H5 and H1. In 871 domestic cats, four (0.46%; 95% CI: 0.13-1.2) sera were HPAI H5 positive and none were confirmed but 40 (4.6%; 95% CI: 3.3-6.2) sera were seropositive for H1 and 26 were confirmed. Stray cats living in nature reserves (odds ratio (OR) = 5.4; 95% CI: 1.5-20.1) and older cats (OR = 3.8; 95% CI: 2.7-7.1) were more likely to be HPAI H5 seropositive. No influenza A virus was detected in 230 cats.ConclusionThe higher HPAI H5 seroprevalence in stray cats compared with domestic cats suggests more frequent viral exposure, most likely due to foraging on wild birds. In contrast, exposure to H1 was more common in domestic cats compared with stray cats.

Use of “ARRIAH-AviFluVac” vaccine in turkeys, geese and ducks

“ARRIAH-AviFluVac” vaccine against H5 avian influenza was demonstrated to be effective for ducks, geese and turkeys both in the laboratory and production environment. When administered to ducks at 0.5; 1.0 and 1.5 cm3, the vaccine provided 100%-effective protection of birds against the disease and death after challenge with the relevant high pathogenicity avian influenza virus of subtype H5N1, clade 2.3.4.4b. Singular 0.5–1.5 cm3 inoculation induced formation of antibodies, which were detected in the hemagglutination inhibition test at the titres that ranged from 4.3 to 6.1 log2. The vaccine facilitated 9–26-fold decrease in the virulent virus shedding by the ducks. Protection of turkeys vaccinated at the dose of 1.0 cm3 was maintained at the level of 87.5% after challenge with high pathogenicity avian influenza virus of subtype H5N1, clade 2.3.4.4b. The vaccine induced formation of antibodies at the titres of 4.9 and 5.5 log2 in turkeys after singular and double vaccination at the dose of 1.0 cm3, respectively. It was demonstrated, that after double administration of 1.0 cm3 of “ARRIAH-AviFluVac” vaccine, the post-vaccinal avian influenza antibody level exceeded 5.0 log2 in 75.9–90.0% of the geese population. The most appropriate way of the vaccine use in turkeys, ducks and geese involves at least its double administration at the double commercial dose. Higher species resistance of ducks to the challenge with avian influenza virus of subtype H5, clade 2.3.4.4bas compared to turkeys was also demonstrated.

A Serum Multi-Parametric Analysis Identifies an Early Innate Immune Signature Associated to Increased Vaccine-Specific Antibody Production and Seroconversion in Simultaneous COVID-19 mRNA and Cell-Based Quadrivalent Influenza Vaccination.

In this pilot study, a multi-parametric analysis comparing immune responses in sera of adult healthy subjects (HS) or people with type 2 diabetes mellitus (T2D) undergoing the single or simultaneous administration of mRNA-based COVID-19 and cellular quadrivalent inactivated influenza vaccines was conducted. While SARS-CoV-2 antibodies remains comparable, influenza antibody titers and seroconversion were significantly higher upon simultaneous vaccination. Magnitude of anti-influenza humoral response closely correlated with an early innate immune signature, previously described for the COVID-19 vaccine, composed of IL-15, IL-6, TNF-α, IFN-γ, CXCL-10 and here extended also to acute-phase protein Pentraxin 3. People with T2D receiving simultaneous vaccination showed a protective response comparable to HS correlating with the early induction of IFN-γ/CXCL10 and a significant reduction of the circulating glucose level due to increased oxidation of glucose digestion and consumption. These data, although preliminary and in-need of validation in larger cohorts, might be exploited to optimize future vaccination in people with chronic disorders, including diabetes.

Gyrfalcon Disease Ecology: A Survey Across Western Alaska

ABSTRACT The Gyrfalcon (Falco rusticolus) is a top avian predator, an Arctic specialist, and among the bird species most vulnerable to climate change. This vulnerability is driven by their narrow ecological niche, limited or lack of southward migration, and circumpolar distribution where the most rapid climatic changes are occurring. Climatic and habitat changes may alter Gyrfalcon disease ecology due to changes in vector distributions, host ranges, and pathogen life cycles. Warmer Arctic temperatures and accompanying landscape changes may also alter the Gyrfalcon’s prey base, and dietary habits can influence transmission of pathogens. To better understand disease ecology in Gyrfalcons, we compared pathogen prevalence across varying time periods at three study sites in Alaska—the Seward Peninsula (2014–2022), the Alaska Peninsula (2021–2022), and the Yukon–Kuskokwim Delta (2008–2013). We collected Gyrfalcon whole blood, thin blood films, cloacal swabs, and fecal samples for serology, haemoparasite assays, microbiological cultures, and fecal tests for parasites. An aliquot of whole blood preserved on filter paper or in Longmire solution was kept for molecular diagnosis of haemoparasites. Serology revealed high exposure to Salmonella (77%), low seroprevalence of avian influenza antibodies (1.5%), exposure to falcon adenovirus type 1 in hatch-year Gyrfalcons (1.3%), and the first report of a Leucocytozoon spp. blood parasite in a Gyrfalcon. We found no antibodies indicative of prior exposure to avian paramyxovirus, West Nile virus, or Chlamydia. One nestling and one hatch-year bird sampled (2 of 12) on the Seward Peninsula exhibited oral plaques from capillarids (Eucoelus spp.) in contrast to those trapped in the Izembek National Wildlife Refuge on the Alaska Peninsula (0 of 6).

Supplementation of Azolla microphylla Flour in Broiler Feed Increases Antibody Titers against Avian Influenza and Newcastle Disease

This study aimed to determine the level of protection provided by supplementation of Azolla microphylla flour in broiler feed against the antibody titers profile of Avian Influenza and Newcastle Disease. The research was conducted over two months (July-August 2021) at the broiler unit of the Integrated Field Laboratory, Faculty of Agriculture, University of Lampung. The experimental design was a Completely Randomized Design with four treatments and five replications. Each replication consisted of five Cobb CP707 strain broilers, resulting in 100 broilers. Azolla microphylla flour supplementation in the feed was administered at different doses: P0=100% commercial feed (control); P1=97.5% commercial feed + 2.5% Azolla microphylla flour; P2=95% commercial feed + 5% Azolla microphylla flour; P3=92.5% commercial feed + 7.5% Azolla microphylla flour. Serum samples were collected from 30-day-old broilers, with one sample taken from each replication, totalling 20 samples. The samples were analyzed for Avian Influenza and Newcastle Disease antibody titers at AGRILab Vaksindo Laboratory using the Hemagglutination Inhibition test. Each treatment's antibody titer data for Avian Influenza and Newcastle Disease were tabulated and presented in histograms to facilitate descriptive analysis. Antibody titers (log2 X) of Avian Influenza 4.00±0.71 and Newcastle Disease 4.60±2.07 from P2 were included in the protection level based on the WOAH Standard. The study concluded that supplementing 5% Azolla microphylla flour in broiler feed increases the antibody titers against Avian Influenza and Newcastle Disease to protective levels.

Influenza antibody breadth and effector functions are immune correlates from acquisition of pandemic infection of children

Cross-reactive antibodies with Fc receptor (FcR) effector functions may mitigate pandemic virus impact in the absence of neutralizing antibodies. In this exploratory study, we use serum from a randomized placebo-controlled trial of seasonal trivalent influenza vaccination in children (NCT00792051) conducted at the onset of the 2009 H1N1 pandemic (pH1N1) and monitored for infection. We found that seasonal vaccination increases pH1N1 specific antibodies and FcR effector functions. Furthermore, prospective baseline antibody profiles after seasonal vaccination, prior to pH1N1 infection, show that unvaccinated uninfected children have elevated ADCC effector function, FcγR3a and FcγR2a binding antibodies to multiple pH1N1 proteins, past seasonal and avian (H5, H7 and H9) strains. Whereas, children that became pH1N1 infected after seasonal vaccination have antibodies focussed to seasonal strains without FcR functions, and greater aggregated HA-specific profiles for IgM and IgG3. Modeling to predict infection susceptibility, ranked baseline hemagglutination antibody inhibition as the highest contributor to lack of pH1N1 infection, in combination with features that include pH1-IgG1, H1-stem responses and FcR binding to seasonal vaccine and pH1 proteins. Thus, seasonal vaccination can have benefits against pandemic influenza viruses, and some children already have broadly reactive antibodies with Fc potential without vaccination and may be considered ‘elite influenza controllers’.

Effects of Combinations of Dietary Vitamin C and Acetylsalicylic Acid on Growth Performance, Carcass Traits and, Serum and Immune Response Parameters in Broilers.

This study aimed to investigate the combined effects of ascorbic acid (VC) and acetylsalicylic acid (ASA) on broiler health and performance. A total of 200 Ross 308 male broilers were divided into five groups, each receiving different dietary combinations of ASA and VC (ASA: 50 or 100 mg/kg; VC: 200 or 400 mg/kg). The 42-day trial assessed parameters such as feed intake, average daily gain (ADG), feed conversion ratio (FCR), carcass characteristics, serum parameters, immune response and cecal microbial flora. The results indicate significant treatment effects on feed intake and growth performance, with a higher feed intake of ADG and FCR in treatment groups (p < 0.05). Serum lipid parameters were unaffected, but creatine kinase increased with ASA and VC intake (p < 0.05). Changes in sheep red blood cell titers and influenza antibodies were noted (p < 0.05). The combination of ASA and VC positively influenced carcass traits, reducing abdominal fat and altering the ratio of immune response organs to body weight (p < 0.05). Additionally, the cecal E. coli count decreased with treatment (p < 0.05). This study underscores the intricate interactions between ASA and VC supplementation, growth performance and carcass composition and immune response in broilers. Further research is warranted to explore dosage nuances and variations under specific stress conditions.

Effect of mineral premix addition to feed on performance of SAN laying hens

Specific Antibody Negative (SAN) laying hens are chickens that have been raised from eggs with a history of negative Avian Influenza (AI) antibody results and negative antigen tests. This research aims to determine the effect of adding organic mineral premix to feed on the SAN performance of laying hens. This study used 72 laying hens aged 43 weeks which were divided into three treatment groups. Each treatment was repeated three times, each consisting of eight chickens, and kept for 35 days. The treatments given consisted of commercial feed without the addition of mineral premix as a control, commercial feed with the addition of 0.25% mineral premix, and commercial feed with the addition of 0.50% mineral premix. The parameters observed were egg production, feed consumption, feed conversion ratio and AI subtype H5 antibody titer results. The data analysis used was a one-way completely randomized design. The results of the study showed that giving mineral premix feed up to 0.50% did not affect the performance of SAN laying hens, so that the addition of mineral premix in feed up to 0.50% has not been able to increase the egg production of SAN hens, but is still able to produce eggs that are suitable as a medium viral AI H5N1.

Engineering of novel hemagglutinin biosensors for rapid detection and drug screening of Influenza A H7N9 virus

New pathogenic influenza virus strains are constantly emerging, posing a serious risk to both human health and economic growth. To effectively control the spread of this virus, there is an urgent need for early, rapid, sensitive, simple, and cost-effective detection technologies, as well as new and effective antiviral drugs. In this study, we have successfully achieved a significant milestone by successfully fusing the H7N9 influenza virus hemagglutinin (HA) protein with the nano-luciferase component, resulting in the development of a novel set of biosensors. This remarkable achievement marks the first instance of utilizing this biosensor technology for influenza antibody detection. Our biosensor technology also has the potential to facilitate the development of antiviral drugs targeting specific epitopes of the HA protein, providing a promising avenue for the treatment of H7N9 influenza virus infections. Furthermore, our biosensors have broad applications beyond H7N9 influenza virus detection, as they can be expanded for the detection of other pathogens and drug screening applications in the future. By providing a novel and effective solution to the detection and treatment of influenza viruses, our biosensors have the potential to revolutionize the field of infectious disease control.

A Multiseason Randomized Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants With Chronic Disease or Older Age.

The aim of the current study was to determine the safety and immunogenicity of trivalent inactivated influenza vaccine (TIV) alone or formulated with Advax delta inulin adjuvant in those who were older (aged >60 years) or had chronic disease. Over 4 consecutive years from 2008 through 2011, adult participants with chronic disease or >60 years of age were recruited into a randomized controlled study to assess the safety, tolerability and immunogenicity of Advax-adjuvanted TIV (TIV + Adj) versus standard TIV. The per-protocol population with ≥1 postbaseline measurement of influenza antibodies comprised 1297 participants, 447 in the TIV and 850 in the TIV + Adj) group. No safety issues were identified. Variables negatively affecting vaccine responses included obesity and diabetes mellitus. Advax adjuvant had a positive impact on anti-influenza immunoglobulin M responses and on H3N2 and B strain seropositivity as assessed by hemagglutination inhibition. TIV + Adj was safe and well tolerated in individuals with chronic disease. There is an ongoing need for research into improved influenza vaccines for high-risk populations. Australia New Zealand Clinical Trial Registry: ACTRN 12608000364370.

Analytical modeling and numerical simulation of graded JAM Split Gate-All-Around (GJAM-SGAA) Bio-FET for label free Avian Influenza antibody and DNA detection

This manuscript presents the analytical model of a novel biosensor called Graded JAM Split Gate-All-Around (GJAM-SGAA) Bio-FET for the detection of Avian Influenza antibody and DNA. The GJAM-SGAA Bio-FET utilizes a silicon Gate-All-Around FET which operates in the Junctionless Accumulation Mode (JAM), with a graded doping in the channel. This Bio-FET also features a gate underlap double sided cavity that enables detection of biomolecules without the use of labels. Gate underlap cavities overcome the fabrication complexity of nanocavities and provides structural stability. A comparative analysis between the GJAM-SGAA Bio-FET and non-graded JAM Split Gate-All-Around FET (SGAA-FET) demonstrates that the proposed BioFET has 5.72 times higher ION current sensitivity, 5.3 times increase in threshold voltage sensitivity (SVth), and 2.13 × 102 times improvement in switching ratio sensitivity for avian influenza biomolecule. The SVth of proposed biosensor is compared with the existing biosensors and found that a triple-metal engineered gate and graded doped channel substantially boosts the sensitivity of proposed biosensor.

Stringent and complex sequence constraints of an IGHV1-69 broadly neutralizing antibody to influenza HA stem

IGHV1-69 is frequently utilized by broadly neutralizing influenza antibodies to the hemagglutinin (HA) stem. These IGHV1-69 HA stem antibodies have diverse complementarity-determining region (CDR) H3 sequences. Besides, their light chains have minimal to no contact with the epitope. Consequently, sequence determinants that confer IGHV1-69 antibodies with HA stem specificity remain largely elusive. Using high-throughput experiments, this study reveals the importance of light-chain sequence for the IGHV1-69 HA stem antibody CR9114, which is the broadest influenza antibody known to date. Moreover, we demonstrate that the CDR H3 sequences from many other IGHV1-69 antibodies, including those to the HA stem, are incompatible with CR9114. Along with mutagenesis and structural analysis, our results indicate that light-chain and CDR H3 sequences coordinately determine the HA stem specificity of IGHV1-69 antibodies. Overall, this work provides molecular insights into broadly neutralizing antibody responses to influenza virus, which have important implications for universal influenza vaccine development.

Influenza Vaccine Type-Dependent Antibody Response in Patients with Autoimmune Inflammatory Rheumatic Diseases.

The study aimed to explore influenza antibody response in patients with autoimmune inflammatory rheumatoid diseases (AIIRDs) stratified by the different vaccine types applied in Denmark during the 2018-2019 influenza season. Included patients were diagnosed with rheumatoid arthritis, psoriatic arthritis, or spondyloarthritis receiving biological disease-modifying antirheumatic drugs (bDMARDs) with or without conventional synthetic disease-modifying antirheumatic drugs. Influenza vaccination status in the 2018-2019 season and vaccine type received were reviewed in the Denmark. Blood samples were drawn ≥ 14 days post vaccination, and antibody titers were determined by the hemagglutinin inhibition (HAI) assay for the serotypes A/Michigan/H1N1, A/Singapore/H3N2, and B/Colorado included in the influenza vaccines in the 2018-2019 season. An overall serotype HAI geometric mean titer (GMT) was calculated from the 3 serotype-specific HAI titers. An overall serotype HAI GMT ≥ 40 was considered protective. Of the 205 included patients, 105 (51%) had received influenza vaccination. One-quarter of vaccinated patients achieved post-vaccination overall serotype HAI GMT ≥40. For patients vaccinated with Influvac, a significantly higher proportion had HAI titers ≥ 40 for 2 serotypes, namely, A/Michigan/H1N1 and A/Singapore/H3N2, than patients vaccinated with Vaxigrip or VaxigripTetra. The same applied to all serotypes HAI GMT, where significantly more patients who received Influvac achieved postvaccination HAI GMT≥40 versus patients who received Vaxigrip (p=0.02) or VaxigripTetra (p=0.002). The latter outcome was explored in a multivariable logistic regression analysis and remained significant when including the following variables: age, sex, treatment with methotrexate and/or prednisolone, type of influenza vaccine, time interval from vaccination to antibody measurement, and previous vaccination status. Influenza antibody levels following vaccination with Influvac in bDMARD-treated patients with AIIRDs were superior to Vaxigrip and VaxigripTetra. Treatment with methotrexate (MTX) did not reduce the antibody response.

Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022-2023 Winter Season.

Vaccination against COVID-19 and influenza provides the best defense against morbidity and mortality. Administering both vaccines concurrently may increase vaccination rates and reduce the burden on the healthcare system. This study evaluated the immunogenicity of healthcare workers in Israel who were co-administered with the Omicron BA.4/BA.5 bivalent COVID-19 vaccine and the 2022-2023 quadrivalent influenza vaccine. SARS-CoV-2 neutralizing antibody titers were measured via microneutralization while influenza antibody titers were measured via hemagglutination inhibition. No immunogenic interference was observed by either vaccine when co-administered. Antibody titers against SARS-CoV-2 variants increased significantly in the cohort receiving the COVID-19 vaccine alone and in combination with the influenza vaccine. Antibody titers against the A/H1N1 influenza strain increased significantly in the cohort receiving the influenza vaccine alone and in combination with the COVID-19 vaccine. Antibody titers against B/Victoria increased significantly in the cohort that received both vaccines. This study has important public health implications for the 2023-2024 winter season, and supports co-administration of both vaccines as a viable immunization strategy.

Influence of dietary mannan-oligosaccharides supplementation on hematological characteristics, blood biochemical parameters, immune response and histological state of laying hens

This study aimed to determine the influence of dietary mannan-oligosaccharides (MOS) on the immune system, hematological traits, blood biochemical parameters, and histological state of laying hens. At 34 wk of age, The Mandarah chicken strain's 120 laying hens and 12 cocks were divided into 4 groups, each with 30 hens and 3 cocks. The first group performed as a control group, which nourished on a basal diet. The second, third, and fourth experimental groups received 0.1, 0.2, and 0.5 g/kg of MOS and a base diet, respectively. Birds obtained MOS at numerous doses significantly (P ˂ 0.05) raised serum levels of immunoglobulin Y (IgY), immunoglobulin M (IgM), and avian influenza (AI) antibodies compared to control birds. Furthermore, adding MOS at a level of 0.1 g/kg diet significantly improved the immune response of the control group. Additionally, compared to the control group, treated birds with MOS at various dosages did not significantly enhance hematological parameters such as red blood cells (RBCs), white blood cells (WBCs), hemoglobin, and hematocrit. Compared to control birds, birds fed MOS at all levels exhibited considerably lower serum cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) values. Also, compared to other treated birds, MOS-treated birds displayed improved histological examination of the small intestine, isthmus, and testis compared to the control group, particularly in birds fed MOS at 0.1 and 0.2 g/kg diet. It could be concluded that using MOS at 0.1 or 2 g/kg diet can successfully improve the physiological performance and overall health of laying hens.

Avian Influenza Surveillance in Pigs, Dogs, Chickens and Slaughter Slabs Biosecurity in Kaduna Metropolis, Nigeria

Avian influenza is a zoonotic disease likely to be exposed to dog, pig and poultry owners &amp; their processors who are in close contact during processing of these animals in Kaduna Metropolis, Nigeria. The study assessed the biosecurity practice of processors in pig, poultry, and dog slaughter slabs; and the prevalence of Avian Influenza (H5 subtype) antibodies in dogs, pigs, and chickens in Kaduna Metropolis. The slaughter slab biosecurity practices were evaluated using questionnaires while the H5 antibodies surveillance was determined by hemagglutination inhibition test. Serum samples from 45 dogs, 104 pigs and 75 chickens were tested for H5 subtype. H5 subtype antibodies prevalence in dogs was 2.2% with a mean titre of 9.0 ± 0 log2 while prevalence and mean titre in chicken were 6.7% and 8.5 ± 0.32 log2 respectively. All pig sera tested were negative for H5 subtype antibodies. The chicken H5 subtype prevalence in central market and railway station live bird markets were 4.3% and 13% respectively. H5 subtype antibodies were present in dogs and chickens in Kaduna metropolis. There is the need for targeted surveillance of avian influenza in dogs and pigs should be incorporated in the national avian influenza surveillance program.

Survival at older ages: Are greater influenza antibody titers protective?

Antibodies are a core element of the immune system’s defense against infectious diseases. We hypothesize that antibody titres might therefore be an important predictor of survival in older individuals. This is important because biomarkers that robustly measure survival have proved elusive, despite their potential utility in health care settings. We present evidence supporting the hypothesis that influenza antibody titres are associated with overall survival of older individuals, and indicate a role for biological sex in modulating this association. Since antibody titres can be altered by vaccination, these results have important implications for public health policy on influenza control in aging populations.

Long-term influenza antibodies profiles in previously vaccinated and non-vaccinated adults

ABSTRACT The aim of this work is to describe the dynamics of influenza antibodies after vaccination in adults. We conducted a case-cohort serological study in the automobile manufacturing plants of the Renault España S.A. group in Valladolid and Palencia (Spain), including 550 workers (66.9%) previously vaccinated against influenza (group V), and 272 (33.1%) never vaccinated (group NV). A pre-vaccination serum sample was collected, another after 30–40 days and another after 6 months. The dynamics of antibodies were analyzed. A lower seroprotection of NV before vaccination was observed, but an antibody response between 2 and 4 times higher than in V was assessed. After 6 months, antibodies declined in both groups until equalize. Antibodies titers decrease with age, and no differences were found among underlying pathologies. Adults never vaccinated against influenza had lower seroprotection than those previously vaccinated, but influenza vaccination produces a more intense serological response in them, acquiring significantly higher antibody titers than those previously vaccinated. The antibodies, although in lower titers, persist and equalize among both groups at least 6 months after vaccination, which allows the individual to be protected during the entire circulation of the influenza virus in the same season.

The impact of pre-existing influenza antibodies and inflammatory status on the influenza vaccine responses in older adults.

Age-associated immune changes and pre-existing influenza immunity are hypothesized to reduce influenza vaccine effectiveness in older adults, although the contribution of each factor is unknown. Here, we constructed influenza-specific IgG landscapes and determined baseline concentrations of cytokines typically associated with chronic inflammation in older adults (TNF-α, IL-10, IL-6, and IFN-γ) in 30 high and 29 low influenza vaccine responders (HR and LR, respectively). In a background of high H3 antibody titers, vaccine-specific H3, but not H1, antibody titers were boosted in LRs to titers comparable to HRs. Pre-vaccination concentrations of IL-10 were higher in LRs compared with HRs and inversely correlated with titers of pre-existing influenza antibodies. Baseline TNF-α concentrations were positively correlated with fold-increases in antibody titers in HRs. Our findings indicate that baseline inflammatory status is an important determinant for generating post-vaccination hemagglutinin-inhibition antibodies in older adults, and IgG responses can be boosted in the context of high pre-existing immunity.